CV8102

BIOLOGICAL2 trials

Sponsors

CureVac

Conditions

Carcinoma, Adenoid CysticCarcinoma, Squamous Cell of Head and NeckMelanoma (Skin)RabiesSquamous Cell Carcinoma of the Skin

Phase 1

Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

CompletedNCT02238756

Start: 2014-09-30End: 2016-11-30Target: 72Updated: 2018-06-06

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

CureVacCarcinoma, Adenoid Cystic, Carcinoma, Squamous Cell of Head and Neck, Melanoma (Skin) +1

Start: 2017-09-25End: 2023-02-28Updated: 2021-11-04

Related Papers

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma

Journal for ImmunoTherapy of Cancer2025-02-014 citations

Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity.

2022-11-028 citations

786 Intratumorally administered CV8102 in patients with advanced solid tumors: preliminary results from ongoing expansion part in study 008

Regular and Young Investigator Award Abstracts2022-11-012 citations

784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion

Regular and Young Investigator Award Abstracts2022-11-01

473 Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in phase I clinical trial

Regular and Young Investigator Award Abstracts2021-11-01

800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

2020-11-011 citations

A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.

Journal of Clinical Oncology2020-05-2012 citations

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors

Annals of Oncology2018-10-014 citations